Portrait of a senior woman standing outdoors on a holiday. Senior woman wearing a backpack and jacket standing during a trekking trip.

Bringing hope through science

Oncopeptides AB (publ) is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. We are science driven, entrepreneurial, and committed to bringing innovation to our patients. Our vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

Read more about Oncopeptides

NKEngage Grant Project Completed

November 12, 2025 – The NKEngage project, funded under the Eurostars program (Vinnova/Eureka), has successfully concluded after achieving its research goals. The consortium delivered preclinical proof-of-concept for a novel affibody polypeptide designed for Natural Killer (NK) cell-mediated immunotherapy targeting multiple myeloma (MM) — an aggressive and currently incurable blood cancer.

Read more

Oncopeptides to host Capital Markets Update November 13

October 23, 2025 – Oncopeptides will host a Capital Markets Update on November 13, 2025, from 09:00 to 12:00 CET, broadcast live from Inderes studio in Stockholm.
The event will provide shareholders and investors with a deeper understanding of the company’s strategic direction, growth plans, and expanding role in the evolving treatment landscape for multiple myeloma.

Read more and register

CEO Sofia Heigis - Oncopeptides AB

Released November 5, 2025

Oncopeptides publishes Q3 report 2025

Read report

Download

“The third quarter of 2025 was a solid and strategically important period for Oncopeptides as we reached several important milestones for continued growth into 2026”

CEO Sofia Heigis

 

See the Webcast

The presentation as PDF

 

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Year-end Report 2025 will be published February 19, 2026

Company news

Notice to Annual General Meeting at Oncopeptides AB (publ)

April 16, 2025

The shareholders in Oncopeptides AB are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m.

Read more

Oncopeptalks – first order in Italy and Q4 report

March 13, 2025

In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.

Read more

Oncopeptides receives first order of Pepaxti in Italy

March 11, 2025

Read more

Science news

NKEngage Grant Project Completed

November 12, 2025

The NKEngage project, funded under the Eurostars program (Vinnova/Eureka), has successfully concluded after achieving its research goals.

Read more

Annals of Hematology: Expert consensus supports use of Pepaxti in myeloma

November 11, 2025

Oncopeptides today announced that a panel of leading multiple myeloma experts has published clinical recommendations for the optimal use of melflufen (branded in Europe as Pepaxti) in Annals of Hematology.

Read more

Research by top universities together with Oncopeptides on NK cell engagers to be presented at ASH

November 3, 2025

Oncopeptides today announces that a collaborative study within the Eurostars funded project NKENGAGE has been accepted as a poster and will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in San Diego, California, between December 6–9, 2025.

Read more

Investor news

CEO Sofia Heigis interviewed by Redeye

November 5, 2025

Redeye’s analyst Richard Ramanius interviews Sofia regarding the Q3 report 2025.

Read more

Invitation to presentation of the Q3 report 2025

October 29, 2025

Oncopeptides AB will publish the report for the third quarter 2025, at 08:00 CET on November 5, 2025. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on November 5 at 09:00 CET.

Read more

Oncopeptides to host Capital Markets Update November 13

October 23, 2025

Oncopeptides will host a Capital Markets Update on November 13, 2025, from 09:00 to 12:00 CET, broadcast live from Inderes studio in Stockholm.

Read more

All Company news

All Science news

All Investor news

Press release - November 11, 2025

Annals of Hematology: Expert consensus supports use of Pepaxti in myeloma

Read press release

Latest press releases

All press releases

Upcoming events

2026-01-19 - 2026-02-18

Silent period

Other

2026-02-19

Year-end report 2025

Report

2026-04-13 - 2026-05-12

Silent period

Other

Full calendar
Senior Hispanic man in wheelchair, with adult son

Vision of Oncopeptides

”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Read more about Oncopeptides

Oncopeptides value words inside the logotype

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.

Read more about our history

Released April 28, 2025

Oncopeptides publishes the 2024 Annual Report

Read report

Download

“2024 was a transformative year for Oncopeptides as we continued our journey toward sustainable growth and expanded access to Pepaxti.”

CEO Sofia Heigis

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Interim Report Q1 2025 will be published May 15, 2025

Oncopeptides via e-mail